Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.60 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | HTR2C | P28335 | 1/20 | 0.60 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.60 |
| ▸ | SCD | O00767 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | TSPO | P30536 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31079626 | 1.00 | MAPK14 (0.65) | MAPK14ADORA3ADORA1ADORA2ACHRM5 | |
| SCHEMBL4258912 | 0.91 | MAPK14 (0.78) | MAPK14ADORA3ADORA1ADORA2AMAPT | |
| SCHEMBL6282312 | 0.88 | ADORA3 (0.73) | ADORA3ADORA1ADORA2ACHRM5HTR2A | |
| SCHEMBL4262622 | 0.85 | MAPK14 (0.75) | MAPK14ADORA3ADORA1ADORA2AMAPT | |
| SCHEMBL5792342 | 0.83 | MAPK14 (0.74) | MAPK14ADORA3ADORA1ADORA2ACHRM5 | |
| SCHEMBL12301018 | 0.82 | ALDH1A1 (0.78) | ADORA3ADORA1ADORA2ACHRM5HTR2A | |
| SCHEMBL6545848 | 0.82 | MAPT (0.59) | ADORA3ADORA1ADORA2ACHRM5HTR2A | |
| SCHEMBL3891927 | 0.81 | MAPT (0.74) | MAPK14ADORA3ADORA2BMAPTMEN1 | |
| SCHEMBL4266079 | 0.81 | MAPK14 (0.78) | MAPK14MAPTMEN1KMT2AUSP2 | |
| SCHEMBL3896242 | 0.80 | ADORA3 (0.67) | MAPK14ADORA3ADORA1ADORA2ACHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4159212-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20220282254-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | FULCRUM THERAPEUTICS INC (US) | 2022-09-08 | — | — | US | disclosed |
| CN-114748622-A | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | 弗尔康医疗公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-114732910-A | P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD | 弗尔康医疗公司 | 2022-07-12 | — | — | CN | disclosed |
| US-20220133704-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | FULCRUM THERAPEUTICS INC (US) | 2022-05-05 | — | — | US | disclosed |
| CN-111601593-B | P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD | 弗尔康医疗公司 | 2022-04-15 | — | — | CN | disclosed |
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | Fulcrum Therapeutics, Inc. (US) | 2022-04-05 | — | — | US | disclosed |
| US-20200383963-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. | 2020-12-10 | — | — | US | disclosed |
| CN-111601593-A | P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD | 弗尔康医疗公司 | 2020-08-28 | — | — | CN | disclosed |
| EP-3691620-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| US-7101899-B1 | 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-09-05 | — | — | US | disclosed |
| US-20060135566-A1 | 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof | OHKAWA SHIGENORI | 2006-06-22 | — | — | US | disclosed |
| WO-2006006691-A2 | SOLID DISPERSION OF A P38 MAP KINASE INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-19 | — | — | WO | disclosed |
| US-20050080113-A1 | Medicinal compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-14 | — | — | US | disclosed |
| US-20040097555-A1 | Concomitant drugs | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-20 | — | — | US | disclosed |
| US-20040063946-A1 | Jnk inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1402900-A1 | MEDICINAL COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| EP-1364949-A1 | JNK INHIBITOR | Takeda Chemical Industries, Ltd. (JP) | 2003-11-26 | — | — | EP | disclosed |
| EP-1354603-A1 | CONCOMITANT DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2003-10-22 | — | — | EP | disclosed |
| EP-1180518-A1 | 5-PYRIDYL-1,3-AZOLE COMPOUNDS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133704-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885ADORA3 4820/4885ADORA1 4837/4885 |
| US-20050080113-A1 | Medicinal compositions | TNF, TRAF6, MMP8 | MAPK14 50/4885ADORA3 1613/4885ADORA1 1594/4885 |
| US-20060135566-A1 | 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof | ADORA3, MAPK4, MAPK3 | MAPK14 47/4885ADORA3 1/4885ADORA1 4/4885 |
| US-20200383963-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, RHOXF2 | MAPK14 193/4885ADORA3 4772/4885ADORA1 4809/4885 |
| US-20040097555-A1 | Concomitant drugs | TNF, CHUK, CNKSR1 | MAPK14 29/4885ADORA3 2584/4885ADORA1 2218/4885 |
| US-20220282254-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885ADORA3 4820/4885ADORA1 4837/4885 |
| US-20040063946-A1 | Jnk inhibitor | MAPK1, MAPK7, MAP3K7 | MAPK14 14/4885ADORA3 4587/4885ADORA1 4358/4885 |
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885ADORA3 4820/4885ADORA1 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.